1. Home
  2. TCRX vs CPHI Comparison

TCRX vs CPHI Comparison

Compare TCRX & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

N/A

Current Price

$0.24

Market Cap

49.4M

Sector

Health Care

ML Signal

N/A

Logo China Pharma Holdings Inc.

CPHI

China Pharma Holdings Inc.

N/A

Current Price

$0.88

Market Cap

41.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TCRX
CPHI
Founded
2018
N/A
Country
United States
China
Employees
N/A
221
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.4M
41.3M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
TCRX
CPHI
Price
$0.24
$0.88
Analyst Decision
Hold
Analyst Count
5
0
Target Price
★ $1.00
N/A
AVG Volume (30 Days)
761.4K
★ 3.9M
Earning Date
11-11-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 12.28
N/A
EPS
N/A
★ N/A
Revenue
★ $10,325,000.00
$4,144,268.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 266.65
N/A
52 Week Low
$0.22
$0.38
52 Week High
$2.57
$19.19

Technical Indicators

Market Signals
Indicator
TCRX
CPHI
Relative Strength Index (RSI) 24.14 55.89
Support Level N/A $0.53
Resistance Level $0.37 $0.91
Average True Range (ATR) 0.03 0.15
MACD 0.01 0.04
Stochastic Oscillator 12.62 42.24

Price Performance

Historical Comparison
TCRX
CPHI

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.

Share on Social Networks: